Bristol Myers Squibb
[1] Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.[9] He went on to self-publish an alternative to the U.S. Pharmacopeia titled Squibb's Ephemeris of Materia Medica, after failing to convince the American Medical Association to incorporate higher purity standards.[33] The company has since settled with the United States Department of Justice and Securities and Exchange Commission, agreeing to pay $150 million, while neither admitting nor denying guilt.[35] On 15 March 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years.[41] Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by Forbes magazine.[46] In December 2014, the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies.In March, the company obtained an exclusive opportunity to both licence and commercialise PROSTVAC, Bavarian Nordic's phase III prostate-specific antigen targeting cancer immunotherapy.[44] In late February 2017, The Wall Street Journal and Fortune, among others, reported that activist investor Carl Icahn had taken a stake in the company, signaling a potential future takeover[50][51] from the likes of Gilead Sciences.[52] In April 2018, the company reported net income of $1.5 billion, or 91 cents per share, for the first quarter of the year, thanks to the increased sales of their cancer drug Opdivo.[53] In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships, and acquisitions.[citation needed] Bristol Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce hepatitis C drugs.[63] In August 2017 the company acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against Merck & Co's cancer rival treatment, Keytruda.[77] In October, BMS announced it would acquire cardiology company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM), and the development of two key treatments: danicamtiv (MYK-491) and MYK-224.[78] In June 2022, BMS announced it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash ($76 per share, a 122.5% premium to its last closing price), helping to boost its complement of cancer drugs, specifically repotrectinib.[81] In September 2023, BMS announced it would pay Zenas BioPharma $50m upfront for a strategic license and collaboration to develop and commercialise obexelimab,[82] a novel, bi-functional antibody for autoimmune diseases.[95] The following is a list of key pharmaceutical products:[96] Cardiovascular diseases Diabetes mellitus Infectious diseases, including HIV infection and associated conditions Inflammatory disorders Oncology Psychiatry Rheumatic disorders Transplant rejection (Former Bristol-Myers brands, now divested) The following is a selective list of investigational products under development, as of 2023:[99] Bristol-Myers Squibb engages with the public and private sectors through the promotion of research and development, academic funding, event sponsorship, philanthropy, and political lobbying.Bristol-Myers Squibb, Johns Hopkins University and the Rockefeller Foundation are currently the subject of a $1 billion lawsuit from Guatemala for "roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis".
The Bristol-Myers Squibb Children's HospitalBMY (disambiguation)Lawrence, New JerseyTrade namePublicTraded asS&P 100S&P 500PharmaceuticalsWilliam McLaren BristolJohn Ripley MyersE. R. SquibbPrinceton, New JerseyLawrenceville, New JerseychairmanOperating incomeNet incomeTotal assetsTotal equitydoing business aspharmaceutical companyfiscalbiologicscancerHIV/AIDScardiovascular diseasediabeteshepatitisrheumatoid arthritispsychiatric disordersresearch and developmentPrincetonSummit, New JerseyCelgeneNew Brunswick, New JerseyRedwood City, CaliforniaSevilleDevensCambridge, MassachusettsBraine-l'AlleudHyderabadBangaloreWirralWallingford, ConnecticutEdward Robinson SquibbBrooklynU.S. PharmacopeiaAmerican Medical AssociationAmerican Journal of PharmacyAmerican Civil WarmorphinequinineHamilton CollegeClintonSal HepaticalaxativeClairolDrackettWindexacidophilus milkEast Syracuse, New YorkpenicillinWorld War II Allied forcesBristol Laboratoriesantibioticsbiologic medicinesNational Medal of Technologyaccounting scandalchannel stuffingUnited States Department of JusticeSecurities and Exchange CommissionPlavixcollusionFrederick B. LaceyPeter DolanLamberto AndreottiForbes magazinenivolumabPROSTVACBavarian NordicAndreottiexecutive chairmanThe Wall Street JournalFortuneCarl IcahnGilead SciencesbiotechnologyMedarexMead Johnson NutritionZymoGeneticsGileadPharmassethepatitis CAmylin PharmaceuticalsEli LillyAstraZenecaacute decompensated heart failureCXL-1427monoclonal antibodyinterleukin-8IFM TherapeuticsMerck & CoKeytrudaOpdivoWellington ManagementStarboard ValueTaishoOtezlaTGF-beta 1TGF-beta 3obstructive hypertrophic cardiomyopathydanicamtivMYK-224repotrectinibobexelimabMirati TherapeuticsXanomelineTrospiumJuno TherapeuticsFortune 500CO2e emissionsirbesartanhydrochlorothiazideSanofiwarfarinapixaban